Manidipine Biogaran

Manidipine, the active ingredient in Manidipine Biogaran, is a calcium channel blocker presented as an oral tablet. It is indicated for the management of hypertension in adult patients, helping to lower elevated blood pressure by relaxing vascular smooth muscle through its vasodilatory effect.

GNH USA supplies Manidipine Biogaran as a licensed, GDP‑compliant international pharmaceutical supplier, providing the product to hospitals, pharmacies and clinics worldwide under strict quality standards and regulatory compliance across global cardiovascular therapy programs.

Manidipine is used to treat disorders of the cardiovascular system, specifically hypertension.

Hypertension: reduction of elevated arterial pressure in adult patients. Primary hypertension: control of high blood pressure when no secondary cause is identified. Essential hypertension: long‑term management of chronic high blood pressure.

Manidipine may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Headache: mild to moderate intensity. - Flushing: sensation of warmth and redness. - Peripheral edema: swelling of the lower limbs. - Dizziness: especially upon standing. - Nausea: occasional gastrointestinal upset. - Tachycardia: increased heart rate.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure requiring medical attention. - Myocardial infarction: rare occurrence of heart attack. - Hepatic dysfunction: abnormal liver enzyme elevations. - Allergic reactions: rash, pruritus, or urticaria. - Angioedema: swelling of face, lips, or throat. - Cardiac arrhythmias: irregular heart rhythms.

Before initiating therapy, clinicians should consider several safety aspects.

Blood pressure monitoring: measure baseline and periodic readings to assess response. Renal impairment: use with caution in patients with reduced kidney function. Hepatic disease: evaluate liver status before prescribing. Concomitant antihypertensives: risk of additive hypotensive effect. Pregnancy and lactation: safety not established; avoid unless clearly needed. Store at ambient temperature: keep in the original container, protect from moisture and light.

Manidipine may interact with other medicines, altering its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors: may increase plasma concentrations of manidipine. - Other calcium channel blockers: additive hypotensive effect. - Phosphodiesterase inhibitors (e.g., sildenafil): risk of severe hypotension.

Moderate Interactions (Monitor Closely): - NSAIDs: may blunt antihypertensive response. - Diuretics: enhanced blood pressure lowering. - Beta‑blockers: monitor for bradycardia and excessive hypotension.